Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Ventyx Biosciences Inc (VTYX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: VTYX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $12
1 Year Target Price $12
| 5 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.6% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 166.52M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 9 | Beta 0.85 | 52 Weeks Range 0.78 - 3.39 | Updated Date 06/29/2025 |
52 Weeks Range 0.78 - 3.39 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.74 |
Earnings Date
Report Date 2025-06-05 | When After Market | Estimate -0.69 | Actual -0.39 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -29.2% | Return on Equity (TTM) -46.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -51386984 | Price to Sales(TTM) - |
Enterprise Value -51386984 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -22.93 | Shares Outstanding 71161200 | Shares Floating 55547722 |
Shares Outstanding 71161200 | Shares Floating 55547722 | ||
Percent Insiders 4.14 | Percent Institutions 74.17 |
Analyst Ratings
Rating 3 | Target Price 12 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Ventyx Biosciences Inc
Company Overview
History and Background
Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel oral therapies for autoimmune and inflammatory diseases. It was founded in 2020. The company's focus is on small molecule therapeutics targeting well-validated biological pathways.
Core Business Areas
- Drug Development: Focused on the development of oral, small molecule therapeutics for immunology indications.
- Clinical Trials: Conducts clinical trials to assess the safety and efficacy of its drug candidates.
- Research and Discovery: Engages in research activities to identify and develop new therapeutic targets and drug candidates.
Leadership and Structure
Ventyx is led by a management team with experience in drug development and commercialization. The company has a board of directors providing governance and strategic oversight.
Top Products and Market Share
Key Offerings
- VTX958: A TYK2 inhibitor being developed for psoriasis, psoriatic arthritis, and Crohn's disease. It is currently in Phase 2 clinical trials. Competitors include BMS's Sotyktu (deucravacitinib).
- VTX3232: An oral peripheral NLRP3 inhibitor being developed for CAPS and other inflammatory conditions. It is currently in Phase 1 clinical trials. Competitors include Olatec Therapeutics's Dapansutrile.
- VTX002: S1P1R Modulator development for Ulcerative Colitis. Preclinical stage.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. It is characterized by long development timelines, high regulatory hurdles, and significant investment in R&D. The immunology market is experiencing growth due to the increasing prevalence of autoimmune and inflammatory diseases.
Positioning
Ventyx Biosciences Inc is positioned as a clinical-stage biopharmaceutical company focused on oral therapies for immunology. Its competitive advantage lies in its pipeline of novel small molecule drug candidates targeting validated biological pathways.
Total Addressable Market (TAM)
The total addressable market for immunology therapeutics is substantial, estimated to be in the tens of billions of dollars annually. Ventyx is positioned to capture a share of this market with its pipeline of oral small molecule drugs.
Upturn SWOT Analysis
Strengths
- Promising pipeline of oral small molecule therapeutics
- Targeting validated biological pathways
- Experienced management team
- Strong financial backing
Weaknesses
- Clinical-stage company with no approved products
- High risk of clinical trial failures
- Reliance on third-party manufacturers
- Relatively short operating history
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Acquisition by a larger company
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Economic downturn impacting R&D investment
Competitors and Market Share
Key Competitors
- BMY
- PFE
- ABBV
Competitive Landscape
Ventyx competes with established pharmaceutical companies with significant resources and expertise. Ventyx's advantage lies in its focus on oral small molecule therapeutics.
Growth Trajectory and Initiatives
Historical Growth: Ventyx's growth is currently driven by its clinical development programs. Positive clinical trial results will be critical for future growth.
Future Projections: Future growth depends on clinical trial success and regulatory approvals. Analyst estimates vary widely due to the inherent uncertainty in drug development.
Recent Initiatives: Advancing VTX958, VTX3232 and VTX002 through clinical trials. Expanding research efforts into new therapeutic targets.
Summary
Ventyx Biosciences Inc. is a high-risk, high-reward clinical-stage company. The company is focused on developing novel oral therapies for autoimmune and inflammatory diseases, with a pipeline of promising drug candidates. Clinical trial success is crucial to the company's future. It is still in its infancy and is up against competitors with strong financial backing.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Ventyx Biosciences Inc. SEC Filings
- Company Investor Relations
- Analyst Reports
- Industry News
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ventyx Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-10-21 | Founder, CEO, President & Director Dr. Raju S. Mohan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 81 | Website https://ventyxbio.com |
Full time employees 81 | Website https://ventyxbio.com | ||
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.